EXPERTS IN DRUG DISCOVERY AND DEVELOPMENT

ENDECE is focused on developing proprietary novel drugs that impact lung inflammation, neuroinflammation and neurodegeneration in chronic, debilitating, and life threatening diseases for which treatment options are limited or non-existent. Our library of proprietary compounds is designed to activate multiple genes within specific biological pathways to stop progression, repair damage, and restore function for people with diseases such as COVID-19 (SARS-CoV-2), Niemann-Pick disease type C (NPC1), Neuromyelitis Optica Spectrum Disorder (NMOSD), Multiple Sclerosis (MS), Alzheimer’s Disease (AD), and Osmotic Demyelination Syndrome (ODS).

 

ANTI-INFLAMMATORY

ENDECE developed NDC-1308, a potential treatment for SARS-CoV-2, which has caused the current COVID-19 pandemic. NDC-1308 has the potential to reduce chronic lung inflammation.

ANTIVIRAL

NDC-1308 may have the ability to reduce the number of ACE2 receptors in the pulmonary system, reducing viral load in SARS-CoV-2 / COVID-19 patients.

REMYELINATION

NDC-1308 directly up-regulates key genes within Oligodendrocyte Progenitor Cells (OPCs) of the Central Nervous System (CNS), inducing OPC differentiation to mature, myelinating Oligodendrocytes.

ENDECE PIPELINE

ENDECE COVID-19 SARS-CoV-2
Niemann-Pick disease type C NPC1
Neuromyelitis Optica Spectrum Disorder NMOSD
Multiple Sclerosis
Alzheimer's Disease
Osmotic Demyelination Syndrome

SARS-CoV-2 / COVID-19

NDC-1308 reduces respiratory distress

  • Lung inflammation
  • Antiviral

Administration:

Inhalation / nebulizor directly to the lungs

  • discovery | preclinical | IND enabeling
  • SARS-CoV-2 is a virus that leads to COVID-19 and is easily spread, overwhelming the health care system and causing worldwide economic distress. ENDECE developed NDC-1308, a novel therapeutic for COVID-19 designed to reduce inflammation in the lungs as well as the number of ACE2 receptors in the pulmonary system, reducing viral load. By reducing pulmonary inflammation and viral load, as well as preventing cytokine storm due to viral infections like SARS-CoV-2 / COVID-19, NDC-1308 should reduce long term effects, keep people off ventilators, and even prevent death.

Niemann-Pick disease type C (NPC1)

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

*RARE DISEASE

  • discovery | preclinical
  • Niemann-Pick disease type C (NPC1) is a rare genetic disorder in which gene mutations are passed from parents to children in a pattern called autosomal recessive inheritance, leading to progressive and lethal neurodegeneration.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

*RARE DISEASE

  • discovery | preclinical
  • Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune disease of the Central Nervous System (CNS) in which the immune system attacks the optic nerve and spinal cord. NMOSD is identified by the presence of antibodies to aquaporin-4 (AQP4), which distinguishes it from MS.

Multiple Sclerosis - Optic Neuritis

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

  • discovery | preclinical
  • Multiple Sclerosis (MS) is an unpredictable, debilitating disease of the Central Nervous System (CNS). Nearly ONE MILLION people are living with MS in the United States, more than twice the original estimates.

Alzheimer’s Disease

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

  • discovery
  • Alzheimer’s Disease has been an irreversible and progressive brain disorder that reduces memory, cognition, and one’s ability to execute the simplest tasks. Symptoms usually appear when a patient is in mid 60’s.

Osmotic Demyelination Syndrome (ODS)

  • Neuroinflamation / Neurodegeneration
  • Administration:
  • Intranasal delivery via nebulizor through the olfactory epithelium to the CNS

  • discovery | preclinical
  • Osmotic Demyelination Syndrome (ODS), also called Central Pontine Myelinolysis (CPM) and Extra Pontine Myelinolysis (EPM), is a demyelination within the pons region of the Central Nervous System (CNS) that interrupts the flow of information between the brain and body.